BioMark Diagnostics (TSE:BUX)
:BUX
Total Valuation
BioMark Diagnostics has a market cap or net worth of C$63.05M. The enterprise value is C$63.28M.
Market CapC$63.05M
Enterprise ValueC$63.28M
Share Statistics
BioMark Diagnostics has 105,090,210 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105,090,210
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioMark Diagnostics’s return on equity (ROE) is 2.34 and return on invested capital (ROIC) is -140.65%.
Return on Equity (ROE)2.34
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-140.65%
Return on Capital Employed (ROCE)8.47
Revenue Per Employee17.14K
Profits Per Employee-214.14K
Employee Count9
Asset Turnover0.15
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioMark Diagnostics is ―. BioMark Diagnostics’s PEG ratio is 0.71.
PE Ratio―
PS Ratio156.67
PB Ratio-41.95
Price to Fair Value-41.95
Price to FCF-25.91
Price to Operating Cash Flow-44.37
PEG Ratio0.71
Income Statement
In the last 12 months, BioMark Diagnostics had revenue of 154.22K and earned -1.93M in profits. Earnings per share was -0.02.
Revenue154.22K
Gross Profit154.22K
Operating Income-1.91M
Pretax Income-1.93M
Net Income-1.93M
EBITDA-1.46M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -1.42M and capital expenditures -629.16K, giving a free cash flow of -2.05M billion.
Operating Cash Flow-1.42M
Free Cash Flow-2.05M
Free Cash Flow per Share-0.02
Dividends & Yields
BioMark Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change140.00%
50-Day Moving Average0.57
200-Day Moving Average0.43
Relative Strength Index (RSI)53.31
Average Volume (3m)16.46K
Important Dates
BioMark Diagnostics upcoming earnings date is Jul 15, 2026, TBA (Confirmed).
Last Earnings DateMar 2, 2026
Next Earnings DateJul 15, 2026
Ex-Dividend Date―
Financial Position
BioMark Diagnostics as a current ratio of 0.16, with Debt / Equity ratio of 140.11%
Current Ratio0.16
Quick Ratio0.16
Debt to Market Cap0.03
Net Debt to EBITDA-1.51
Interest Coverage Ratio-11.43
Taxes
In the past 12 months, BioMark Diagnostics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioMark Diagnostics EV to EBITDA ratio is -29.34, with an EV/FCF ratio of -27.32.
EV to Sales165.18
EV to EBITDA-29.34
EV to Free Cash Flow-27.32
EV to Operating Cash Flow-27.44
Balance Sheet
BioMark Diagnostics has C$1.29M in cash and marketable securities with C$711.78K in debt, giving a net cash position of C$574.41K billion.
Cash & Marketable SecuritiesC$1.29M
Total DebtC$711.78K
Net CashC$574.41K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share>-C$0.01
Margins
Gross margin is -147.92%, with operating margin of -806.71%, and net profit margin of -874.52%.
Gross Margin-147.92%
Operating Margin-806.71%
Pretax Margin-874.52%
Net Profit Margin-874.52%
EBITDA Margin-563.07%
EBIT Margin-803.96%
Analyst Forecast
The average price target for BioMark Diagnostics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-21.89%
EPS Growth Forecast26.36%